Is there evidence supporting coronary revascularization in patients with left ventricular systolic dysfunction?

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 3-10

  Ammirati, Enrico ^a   Rimoldi, Ornella E ^b   Camici, Paolo G ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c Heart Care Foundation   (Italy)

Author keywords

Coronary artery disease; Heart failure; Hibernation; Positron emission tomography; Revascularization

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DISEASE DURATION; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; MYOCARDIAL HIBERNATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMATIC REVIEW; SYSTOLIC DYSFUNCTION; TREATMENT INDICATION; TREATMENT OUTCOME;

CHRONIC DISEASE; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL REVASCULARIZATION; MYOCARDIAL STUNNING; MYOCARDIUM; STROKE VOLUME; SYSTOLE; TIME FACTORS; TISSUE SURVIVAL; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 78651246497     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1164     Document Type: Article

References (45)

1. Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine: The epinephrine ventriculo-gram. Circulation 1974; 49: 1063 -1071.
2. Helfant RH, Pine R, Meister SG, Feldman MS, Trout RG, Banka VS. Nitroglycerin to unmask reversible asynergy: Correlation with post coronary bypass ventriculography. Circulation 1974; 50: 108-113.
3. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998; 339: 173-181.
4. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008; 117: 103-114.
5. Diamond GA, Forrester JS, deLuz PL, Wyatt HL, Swan HJ. Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978; 95: 204-209.
6. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985; 72: V123-V135.
7. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood fow and the severity of coronary-artery stenosis. N Engl J Med 1994; 330: 1782-1788.
8. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
9. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: Diagnosis and patient outcomes. Curr Probl Cardiol 2007; 32: 375-410.
10. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99 m sestamibi SPECT. J Nucl Cardiol 2006; 13: 24-33.
11. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: Role of positron emission tomography. Eur Heart J 2010 [E-pub ahead of print].
12. Marinho NV, Keogh BE, Costa DC, Lammerstma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction: New insights from the measurement of absolute myocardial blood fow and glucose utilization. Circulation 1996; 93: 737-744.
13. CASS. Coronary artery surgery study (CASS): A randomized trial of coronary artery bypass surgery: Survival data. Circulation 1983; 68: 939-950.
14. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010 [E-pub ahead of print].
15. McMurray JJ. Clinical practice: Systolic heart failure. N Engl J Med 2010; 362: 228-238.
16. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
17. Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg 2007; 134: 1540-1547.
18. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
19. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006; 355: 2395-2407.
20. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.
21. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSI II randomized controlled trial. JAMA 2007; 297: 1985-1991.
22. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, et al. Ten-year follow-up of survival and myocardial infarc- tion in the randomized Coronary Artery Surgery Study. Circulation 1990; 82: 1629-1646.
23. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revasculariza-tion Treatment Investigators. N Engl J Med 1999; 341: 70-76.
24. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283-1291.
25. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120: 2529-2540.
26. Cantor WJ, Baptista SB, Srinivas VS, Pearte CA, Menon V, Sadowski Z, et al. Impact of stress testing before percutaneous coronary intervention or medical management on outcomes of patients with persistent total occlusion after myocardial infarction: Analysis from the occluded artery trial. Am Heart J 2009; 157: 666-672.
27. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002; 39: 1151-1158.
28. Tarakji KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006; 113: 230-237.
29. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
30. Ellenbogen KA, Wood MA, Klein HU. Why should we care about CARE-HF? J Am Coll Cardiol 2005; 46: 2199-2203.
31. Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J 2010; 74: 809-817.
32. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381.
33. Kruk M, Buller CE, Tcheng JE, Dzavik V, Menon V, Mancini GB, et al. Impact of left ventricular ejection fraction on clinical outcomes over fve years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). Am J Cardiol 2010; 105: 10-16.
34. Dzavik V, Buller CE, Lamas GA, Rankin JM, Mancini GB, Cantor WJ, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: The Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation 2006; 114: 2449-2457.
35. Kirschbaum SW, Springeling T, Boersma E, Moelker A, van der Giessen WJ, Serruys PW, et al. Complete percutaneous revascular-ization for multivessel disease in patients with impaired left ventricular function: Pre- and post-procedural evaluation by cardiac magnetic resonance imaging. JACC Cardiovasc Interv 2010; 3: 392-400.
36. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet 2003; 362: 14-21.
37. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fuorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50: 2002-2012.
38. Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: The Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med 2010; 51: 567-574.
39. D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing beneft from revascularization is associated with increasing amounts of myocardial hibernation: A substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009; 2: 1060-1068.
40. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, et al. Coronary bypass surgery with or without surgical ven- tricular reconstruction. N Engl J Med 2009; 360: 1705-1717.
41. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
42. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.
43. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defbrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
44. Moss AJ. What we have learned from the family of multicenter automatic defbrillator implantation trials. Circ J 2010; 74: 1038-1041.
45. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Ide T, Takeshita A, et al. Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1442-1447.